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Erythropoietin⁄erythropoietin receptor system is involved in angiogenesis in human
neuroblastoma
Aims: Previous studies have shown that increased
vascularity is associated with tumour progression in
human neuroblastoma (NB). The involvement of ery-
thropoietin (Epo) in tumour angiogenesis has also been
reported. The aim of this study was to correlate
microvascular density and Epo ⁄ Epo-receptor (EpoR)
expression in endothelial and tumour cells to the
clinical stage of NB.
Methods and results: Specimens of NB obtained from 20
patients were investigated immunohistochemically by
using anti-CD31, anti-Epo and anti-EpoR antibodies.
The extent of angiogenesis was found to be up-regu-
lated in advanced disease. In keeping with this
observation, Epo ⁄ EpoR expression in tumour and
endothelial cells, respectively, was also highly correla-
ted with the extent of angiogenesis and higher clinical
stage.
Conclusions: The correlation of Epo ⁄ EpoR expression
with angiogenesis and tumour progression suggests
the presence of a loop in the Epo–EpoR system. Epo is
secreted by tumour cells and affects vascular endothel-
ial cells via its receptor, promoting tumour angiogen-
esis in a paracrine manner. Data suggest that Epo
represents an important mediator in NB angiogenesis.
Understanding the mechanisms of NB angiogenesis
provides the basis for a rational approach to the
development of antiangiogenic therapy in patients
affected by NB.
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Abbreviations: CAM, chorioallantoic membrane; Epo, erythropoietin; FGF-2, ﬁbroblast growth factor-2;
INSS, International Neuroblastoma Staging System; MMP, matrix metalloproteinase; NB, neuroblastoma;
rhEpo, recombinant human Epo; TBS, Tris-buffered saline; VEGF, vascular endothelial growth factor
Introduction
Neuroblastoma (NB) is the most common malignant
tumour in infants and the fourth most common in
children >1 year old.
1 Angiogenesis, i.e. the formation
of new blood vessels from pre-existing ones, is import-
ant in carcinogenesis as well as in the tumour
progression of human solid and haematological
tumours.
2,3 NB, in particular, shows wide histological
variability that reﬂects different steps in tumour mat-
uration and angiogenesis appears to play an important
role in determining tumour phenotype.
4 Many angio-
genic stimulators, such as vascular endothelial growth
factor (VEGF), ﬁbroblast growth factor-2 (FGF-2), as
well as inhibitors, such as tissue inhibitors of matrix
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neuroblastic tumours.
5–7 High tumour vascularity
correlates with metastatic disease, myc ampliﬁcation,
unfavourable biology and poor outcome; by contrast,
low tumour vascularity is associated with favourable
prognostic features, such as localized disease and
favourable histology.
8–11
Erythropoietin (Epo) is a low-molecular-weight glyco-
protein hormonal stimulator of erythropoiesis produced
in the fetal liver and subsequently in the adult
kidney.
12 Epo exerts its action through its speciﬁc
receptor (EpoR), a member of the cytokine receptor
superfamily, which is mainly expressed on erythroid
colony-forming units.
13
Despite its original function, Epo is a pleiotropic
cytokine that exerts various biological functions in
many different non-haematopoietic tissues. Angiogen-
esis has been identiﬁed as one of the extrahaematopoi-
etic functions of Epo.
14 The role of Epo in angiogenesis
has not yet been clariﬁed, although many critical roles
for Epo have been reported. EpoR has been found to be
expressed on endothelial cells from different tissues.
15
Moreover, Epo induces endothelial cell proliferation and
migration
15–17 and has been shown to stimulate angio-
genesis in rat aortic rings in vitro.
18 We have demon-
strated that recombinant human Epo (rhEpo) induces a
proangiogenic phenotype in human endothelial cells.
19
This phenotype includes both early (i.e. increase in cell
proliferation and MMP-2 production) and late (differen-
tiation into vascular tubes) angiogenic events. Accord-
ingly, after rhEpo exposure, endothelial cells express
EpoR that binds to JAK-2 and induces its transient
activation. It isinteresting tonote that JAK-2 is involved
in the intracellular signalling of receptors for various
angiogenic cytokines,
20 suggesting a possible role for
JAK-2 ⁄ STAT-5 signalling in cytokine-mediated angio-
genesis. In the chick embryo chorioallantoic membrane
(CAM) assay, the angiogenic activity of rhEpo is
quantitatively and qualitatively similar to that exerted
by FGF-2 and colocalization of EpoR and factor VIII-
related antigen has been demonstrated on CAM endot-
helial cells. Jaquet et al.
21 have reported that Epo has a
similar angiogenic potential to VEGF in stimulating
human adult myocardial endothelial cells.
The potential role of Epo in angiogenesis may be
considered as a subsidiary of its possible function in
improving overall tissue oxygenation and inhibition of
apoptosis. The expression of EpoR in tumour vascular
endothelium suggests that Epo may affect the tumour
microenvironment, perhaps by stimulating tumour
angiogenesis.
14
Expression of Epo ⁄ EpoR in human NB has been
reported,
31 but a morphometric and quantitative study
is still lacking. In this study, we correlated Epo ⁄ EpoR
expression with vascular density across the whole
spectrum of neuroblastic tumours reﬂecting different
clinical stages. Our aim was to establish a potential role
for Epo in angiogenesis in NB.
Materials and methods
human nb tumour samples
Parafﬁn-embedded sections of 20 archival primary
adrenal and paraspinal human NB tumour samples
were obtained by the Department of Pathology of the
University of Brescia Medical School. The clinical stages
were formulated according to the International Neuro-
blastoma Staging System (INSS).
22 INSS stages I and IIa
include low-risk small tumours which can be managed
by surgery alone; stages IIb and III include patients
with intermediate-risk disease characterized by large,
unresectable, localized tumours without structural
chromosomal defects; stage IV includes high-risk
tumours characterized by disseminated disease with
grossgeneticalterations,suchasampliﬁcationofN-myc;
stageIVsincludesinfants<1 yearoldatdiagnosiswitha
small primary tumour and dissemination of disease.
immunohistochemistry
A murine monoclonal antibody (MAb) against the
human endothelial cell marker CD31, a more sensitive
marker for endothelial cells than factor VIII antigen,
23
(MAb 1A10; DakoCytomation, Glostrup, Denmark),
and two rabbit polyclonal antibodies against Epo and
EpoR (N19 and C20 Santa Cruz Biotechnology, Santa
Cruz, CA, USA) were used. The anti-Epo and anti-EpoR
antibodies are two afﬁnity-puriﬁed rabbit polyclonal
antibodies raised against a peptide mapping at the
N-terminus of Epo and, respectively, against amino
acids 21-214 mapping near the N-terminus of EpoR
of human origin. Brieﬂy, sections were collected on
3-amino-propyl-triethoxysilane-coated slides, deparaff-
inized by the xylene–ethanol sequence, rehydrated in a
graded ethanol scale and in Tris-buffered saline (TBS,
pH 7.6) and incubated overnight at 4 C with the MAb
1A10 (1 : 25 in TBS) and the polyclonal antibodies
N19 and C20 (1 : 200 in TBS), after prior antigen
retrieval by heating the sections in a pressure cooker
in 1 mmol ⁄ l ethylenediamine tetraacetic acid buffer,
pH 8.0, for 1.5 h. As for CD31 immunohistochemistry,
sections were incubated with biotinylated IgG and
then with peroxidase-conjugated streptavidin (LSAB2;
DakoCytomation). Immunodetection of CD31 was by
diaminobenzidine, while Epo and EpoR detection was
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phosphatase (DakoCytomation) and fast red as chro-
mogen, followed by haematoxylin counterstaining.
Negative controls included an unrelated monoclonal
IgG1 produced by the P3X63 ⁄ Ag8 mouse secretory
myeloma replacing the antibody, for the MAb against
CD31
24 and preincubation with a 10-fold excess of
speciﬁc blocking peptide (Santa Cruz) for the polyclonal
antibodies against Epo and EpoR.
microvessel density, epo and epor expression
counting
Four to six 200· ﬁelds for each slide covering almost
the whole of three sections per sample were examined
with a 144-intersection point square reticulum
(0.78 mm
2) inserted in the eyepiece. Particular atten-
tion was paid to selection of microvessels, i.e. capillaries
and small venules, from all CD31+ vessels. They were
identiﬁed as transversely sectioned tubes with a single
layer of endothelial cells, with or without a thin
basement membrane. Each assessment was agreed
upon in turn. Microvessels were counted with a
planimetric point-count method with slight modiﬁca-
tions to restrict counting to transversely cut microves-
sels occupying the reticulum intersection points.
25 As
the microvessel diameter was smaller than the distance
between adjacent points, only one transversely sec-
tioned microvessel could occupy a given point. Micro-
vessels transversely sectioned outside the points and
those longitudinally or tangentially sectioned were
omitted. Therefore, it was sufﬁciently certain that a
given microvessel was counted only once, even in the
presence of several of its section planes. As almost the
entire section was analysed per sample and as trans-
versally sectioned microvessels hit the intersection
points randomly, the method allowed objective counts.
Tumour and endothelial cells positive for CD31, Epo
and EpoR were counted in four to six ﬁelds covering the
whole of each of three sections adjacent to those
stained for microvessels and means ±1 SD and medi-
ans were determined for each section, sample and
group of samples. All analyses were simultaneously
assessed without knowledge of the ﬁnal pathological
diagnosis by two investigators with a double-headed
light microscope (Axioplan II; Zeiss, Oberkochen,
Germany). The relationship between microvessel
density, Epo and EpoR expression and clinical stage
was examined by v
2 test or logistic regression analysis.
Statistical signiﬁcance was deﬁned as P < 0.05.
Results
Histologically, in all the samples examined, microves-
sels have been deﬁned as endothelial cells clustered in
nests or tubes, transversely or longitudinally sectioned,
with or without a small lumen. Figure 1 shows
representative sections of low and high vascularity
of NB immunohistochemically stained with an anti-
CD31 antibody. The microvessel density in stage IVs
(Figure 1C) was higher compared with stages III
(Figure 1B) and I (Figure 1A).
EpoR was diffusely and strongly expressed on endo-
thelial cells within neoplastic nodules (Figure 2),
whereas in most cases Epo showed a weak and focal
cytoplasmic granular pattern in a few NB cells in stages
A C B
Figure 1. Immunohistochemistry for CD31 in human neuroblastoma. The microvessel density is higher in stage IVs neuroblastoma (C)
compared with stage III (B) and I (A).
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increased in stage IVs (Figure 3C).
Table 1 shows the correlation between microvessel,
Epo and EpoR counts and histological tumour grade.
The comparison of microvessel counts between histo-
logical groups revealed statistically signiﬁcant differ-
ences. When differences were sought between groups,
signiﬁcantly higher counts were found in stage IVs
compared with other stages (P<0.001). Regarding
differences in microvessel, Epo and EpoR expression in
A C B
Figure 2. Immunohistochemistry for erythropoietin receptor (EpoR) in human neuroblastoma. The immunoreactivity of endothelial cells for
EpoR is higher in stage IVs neuroblastoma (C) compared with stage III (B) and I (A).
A C B
Figure 3. Immunohistochemistry for erythropoietin (Epo) in human neuroblastoma. Few tumour cells are immunoreactive for Epo in stages I
(A) and III (B), while immunoreactivity is greatly increased in stage IVs (C).
Table 1. Correlation between
International Neuroblastoma Staging
System (INSS) stage, microvessel
density, erythropoietin (Epo) expres-
sion in tumour cells and erythro-
poietin receptor (EpoR) expression
in endothelial cells, expressed as
means ± SD of the number of
positive cells
INSS stages Cases
Microvessel
density
Epo expression,
tumour cells
EpoR expression,
endothelial cells
I + II 10 10 ± 5 9 ± 2 5 ± 2
III + IV 5 15 ± 4* 14 ± 3* 8 ± 4*
IVs 5 30 ± 5* 25 ± 4* 25 ± 6*
*P<0.001 compared with I + II.
Epo–EpoR and angiogenesis in human neuroblastoma 639
  2007 The Authors. Journal compilation   2007 Blackwell Publishing Ltd, Histopathology, 50, 636–641.both endothelial and tumour cells, within-group com-
parison showed that both counts were always signiﬁ-
cantly correlated. There was a trend for these three
parameters to increase with INSS stage. The counts of
patients with stage IVs NB were signiﬁcantly higher
(P<0.001) than those of patients with III + IV and,
respectively, I +II NB.
Discussion
Angiogenesis and tumour progression in human NB
have been correlated. Our data demonstrate that the
extent of angiogenesis in human NB, evaluated as
microvessel density, increases progressively along
with clinical stage. Different molecules and angio-
genic factors are involved in tumour angiogenesis in
human NB. We have demonstrated that the Epo ⁄
EpoR system is involved in NB angiogenesis and that
expression of Epo in tumour cells and of EpoR in
endothelial cells increases in parallel with grade of
malignancy and is highly correlated with the extent
of angiogenesis.
Tumour angiogenesis does not depend on a single
molecule, since many angiogenic inducers and inhibi-
tors are expressed simultaneously. The presence of an
autocrine-paracrine Epo–EpoR system in tumours and
the possible effects of Epo on tumour microenvironment
and angiogenesis are consistent with a complex biology
for Epo–EpoR signalling in cancer.
Kayser and Gabius
26 ﬁrst suggested that human
tumours express EpoR. In their study, 81% of human
lung carcinoma tissues possessed Epo-binding sites,
detected by the use of biotinylated rhEpo. EpoR
transcripts and EpoR protein were subsequently dem-
onstrated in human renal carcinoma,
27 tumours of the
cervix and other organs of the female reproductive
tract
28–30 and in various specimens of common
paediatric tumours, including neuroblastomas, brain
tumours, hepatoblastomas and Wilms’ tumours.
31 By
immunohistochemistry, EpoR has been shown to be
expressed in breast carcinoma
32–34 and in vestibular
schwannoma.
35 Yasuda et al.
36 have reported the
expression of Epo in several malignant human cell
lines, suggesting that they express Epo and EpoR
regardless of origin, type, genetic characteristics and
biological properties. Moreover, the authors have
shown that tumour cells secrete a very small amount
of Epo individually and that most of them respond to
hypoxic stimuli by enhanced secretion of Epo.
Batra et al.
31 have demonstrated that most of the
common paediatric tumours, including NB, express Epo
and EpoR, which promote cell survival genes and
increase release of angiogenic growth factors from
tumour cells. These ﬁndings suggest the presence of a
loop in the Epo–EpoR system, i.e. Epo is secreted by NB
tumour cells and affects vascular endothelial cells via
its receptors and promotes angiogenesis in a paracrine
manner. Thus, it is suggested that Epo is an important
factor in the angiogenesis of human NB.
Understanding the mechanisms of NB angiogenesis
provides a basis for a rational approach to the
development of antiangiogenic therapy in patients
with NB. Inhibition of Epo signalling, by the injection
of anti-Epo MAb or a soluble form of EpoR, resulted in
delay in the growth of ovarian and uterine cancers.
28
In nude mice, Yasuda et al.
36 blocked Epo signalling in
xenografts of two representative cell lines by intraperi-
toneal injection of an EpoR antagonist and found
inhibition of angiogenesis and survival of tumour cells,
leading to destruction of tumour masses. Our results
may have implications for the treatment of human NB
by inhibition of the Epo–EpoR system.
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